About
Tang Capital Acquisition Corp.
Tang Capital Acquisition is a newly formed company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
We intend to focus our search in the biopharmaceutical industry. The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.
Tang Capital Acquisition Corp. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Valuation & Multiples
Key valuation ratios and metrics
Financial Highlights
Historical financial performance
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1/A | Oct 16, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | Oct 6, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS | Aug 31, 2026 | [Cover] Draft Registration Statement |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Kevin Tang
Chair of the Board and Chief Executive Officer
Ryan Cole
Chief Operating Officer
Michael Hearne
Chief Financial Officer
Stew Kroll
Chief Development Officer
Thomas Wei
Chief Scientific Officer
Craig Johnson
Director
Tina S. Nova, Ph.D.
Director
David Ramsay
Director
